Health ❯ Healthcare ❯ Patient Care

Treatment Efficacy

Response Rates Progression-Free Survival Survival Rates Quality of Life Clinical Outcomes Side Effects Management Adverse Effects Long-term Outcomes Side Effects Drug Safety Adverse Events Drug Side Effects Safety Profiles Chemotherapy Resistance Migraine Relief Amyloid Plaques Long-term Monitoring Therapeutic Interventions Patient Preferences Minimal Residual Disease Patient Selection Comparative Effectiveness Biomarkers in ALS Survival Outcomes Toxicity Management Survey Results Patient-Reported Outcomes Immunotherapy Invasive Disease-Free Survival Safety and Tolerability Monotherapy Eltrombopag Adjuvant Therapy Cognitive Decline Exacerbation Rates Chemotherapy and Radiotherapy Asthma Management Hair Growth Solutions Quality of Life Improvements Medication Tolerability Novel Interventions Clinical Trials Remission Rates

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Results presented at SABCS, published in JCO, show a clinically meaningful delay in progression with first-line maintenance tucatinib.

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

Sanofi’s Efdoralprin Alfa Shows Superior Biomarker Response to Plasma Therapy in Phase 2 AATD Trial

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

Bristol Myers’ Iberdomide Combo Hits MRD Goal in Phase 3 Myeloma Study

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

FDA Approves Ionis’ Dawnzera to Prevent Hereditary Angioedema Attacks

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

Modified Herpes Virus Plus Nivolumab Induces Tumor Regression in Advanced Melanoma

Liraglutide Pilot Study Halves Chronic Migraine Days, Paves Way for Randomized Trials